Tags

Type your tag names separated by a space and hit enter

Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Expert Rev Clin Pharmacol. 2014 Sep; 7(5):567-77.ER

Abstract

Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The goal of this article is to discuss current treatment options for rosacea and the properties of brimonidine tartate as well as the evidence surrounding its efficacy and safety profile.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Tong LX
David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Moore AY
No affiliation info available

MeSH

Adrenergic alpha-2 Receptor AgonistsAnimalsBrimonidine TartrateErythemaHumansQuality of LifeQuinoxalinesRosaceaTreatment Outcome

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25091290

Citation

Tong, Lana X., and Angela Yen Moore. "Brimonidine Tartrate for the Treatment of Facial Flushing and Erythema in Rosacea." Expert Review of Clinical Pharmacology, vol. 7, no. 5, 2014, pp. 567-77.
Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol. 2014;7(5):567-77.
Tong, L. X., & Moore, A. Y. (2014). Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Review of Clinical Pharmacology, 7(5), 567-77. https://doi.org/10.1586/17512433.2014.945910
Tong LX, Moore AY. Brimonidine Tartrate for the Treatment of Facial Flushing and Erythema in Rosacea. Expert Rev Clin Pharmacol. 2014;7(5):567-77. PubMed PMID: 25091290.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. AU - Tong,Lana X, AU - Moore,Angela Yen, Y1 - 2014/08/04/ PY - 2014/8/6/entrez PY - 2014/8/6/pubmed PY - 2015/3/31/medline KW - brimonidine KW - brimonidine tartrate KW - facial erythema KW - rosacea KW - rosacea treatment KW - sansrosa SP - 567 EP - 77 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 7 IS - 5 N2 - Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The goal of this article is to discuss current treatment options for rosacea and the properties of brimonidine tartate as well as the evidence surrounding its efficacy and safety profile. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/25091290/Brimonidine_tartrate_for_the_treatment_of_facial_flushing_and_erythema_in_rosacea_ DB - PRIME DP - Unbound Medicine ER -